论文部分内容阅读
目的探讨溶栓对心源性脑栓塞急性期的疗效、安全性及最佳溶栓方法。方法心源性急性脑梗死患者60例被随机分为巴曲酶组、尿激酶组两组,分别以巴曲酶、尿激酶为患者进行溶栓治疗,比较并分析两组的临床疗效和安全性。结果比较显示在心源性脑梗死的急性期治疗中,巴曲酶组的安全性优于尿激酶组,两组比较差异有统计学意义(P<0.05),在疗效方面两组比较差异无统计学意义(P>0.05)。结论心源性脑梗死急性期患者,应用巴曲酶进行溶栓治疗安全性高;对于心源性脑栓塞颈内动脉系者,溶栓效果差。
Objective To investigate the efficacy and safety of thrombolytic therapy in the acute phase of cardiogenic cerebral embolism and the optimal thrombolysis method. Methods Sixty patients with acute cerebral infarction were randomly divided into batroxobin group and urokinase group, and were treated with batroxobin and urokinase respectively. The clinical efficacy and safety of the two groups were compared and analyzed Sex. The results showed that in the acute phase of cardio-cerebral infarction, the safety of batroxobin group was better than that of urokinase group, the difference between the two groups was statistically significant (P <0.05). There was no statistical difference in curative effect between the two groups Significance (P> 0.05). Conclusions In patients with acute cerebral infarction, thrombolytic therapy with batroxobin is safe. For patients with cardiogenic cerebral embolism, the thrombolytic effect is poor.